Abstract Details

Title Does opening access to oral disease modifying therapy increase rates of initiation and reduce disease-related medical costs in a national population of patients with multiple sclerosis?

Topic Multiple Sclerosis

Presentation(s) P3 - (-)

Poster/Presentation
Number 403

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
John Ko, PharmD, MS (Alnylam) PRESENTER	Dr. Ko has received personal compensation for serving as an employee of Alnylam Pharmaceuticals. Dr. Ko has received personal compensation for serving as an employee of Novartis. Dr. Ko has received stock or an ownership interest from Alnylam Pharmaceuticals. Dr. Ko has received stock or an ownership interest from Novartis.
Daniel Kantor, MD, FAAN (Medical Partnership 4 MS+)	Dr. Kantor has received personal compensation for serving as an employee of Gateway Institute for Brain Research. Dr. Kantor has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Bristol Myers Squibb. Dr. Kantor has a non-compensated relationship as a HAP with MSFous (MSF) that is relevant to AAN interests or activities. Dr. Kantor has a non-compensated relationship as a Medical Board with MS Views & News that is relevant to AAN interests or activities.
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Stefan Varga	No disclosure on file
	No disclosure on file
	No disclosure on file

��ɫ��

��ɫ��

Abstract Details

��ɫ����

��ɫ����

��ɫ��

��ɫ��